Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

In contrast with the muted enthusiasm that greeted Amgen, Inc.’s announcement of Phase I data for the combination of its KRAS G12C inhibitor with immune-checkpoint inhibitors, early data for its bispecific antibody tarlatamab in lung cancer generated much more excitement, and the company indicated it may expand the new drug’s reach as well.

Amgen presented data on 8 August at the World Conference on Lung Cancer (WCLC) for tarlatamab, a delta-like ligand 3 (DLL3)-targeting half-life extended bispecific T-cell engager (HLE BiTE), in small-cell lung cancer (SCLC), showing what the company called encouraging antitumor activity and durability of responses